Table 1.
Patient characteristics
| BP | ONJ |
All n = 100 | |
|---|---|---|---|
| (+)n = 17 | (−) n = 83 | ||
| Zoledronic acid | 16 (94.1%) | 78 (94.0%) | 94 (94.0%) |
| Ibandronate | 0 (0%) | 1 (1.2%) | 1 (1.0%) |
| Pamidronate | 0 (0%) | 1 (1.2%) | 1 (1.0%) |
| Combination | 1 (5.9%) | 3 (3.6%) | 4 (4.0%) |
| BP duration | |||
| ≥1 year | 15 (88.2%) | 63 (75.9%) | 78 (78.0%) |
| <1 year | 2 (11.8%) | 14 (16.9%) | 16 (16.0%) |
| Unknown | 0 (0%) | 6 (8.4%) | 6 (6.0%) |
| Race | |||
| Caucasian | 14 (82.4%) | 66 (79.5%) | 80 (80.0%) |
| African American | 2 (11.8%) | 10 (12.0%) | 12 (12.0%) |
| Hispanic | 1 (5.9%) | 5 (6.0%) | 6 (6.0%) |
| Asian | 0 (0%) | 2 (2.4%) | 2 (2.0%) |
| Median age at diagnosis (range) | 60 (48–75) | 59 (43–75) | 59 (43–75) |
Abbreviations: BP, bisphosphonate; ONJ, osteonecrosis of the jaw.